Search

everythinglearnresearchcommunity

for

Search:↓

Teprotumumab for thyroid eye disease commonly causes fatigue, brittle nails, dry eyes, hair loss, muscle spasms, and dry mouth, with rare serious events like blood clots.

Some drugs linked to growth hormones may increase the chance of hair loss in women.

Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.

Trodelvy™ helped some patients with advanced breast cancer, but had side effects.

PROTACs offer a new, precise way to treat cancer by breaking down harmful proteins.

PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

PROTAC technology shows promise for cancer treatment but needs more effective E3 ligase recruiters.

Adding a second method to PROTACs could improve cancer treatment.

PROTACs show promise in cancer treatment by effectively degrading specific harmful proteins.

PROTACs show promise for cancer treatment, but designing them effectively is challenging.

Promising cancer treatments were found, but the manufacturer closed.

Sacituzumab govitecan improves quality of life and extends life for breast cancer patients compared to standard chemotherapy.

Panitumumab treatment can cause unusual hair growth in some colorectal cancer patients.

Sacituzumab govitecan improves quality of life and symptoms in breast cancer patients, except for causing more diarrhea.

Sacituzumab govitecan is effective but has side effects like hair loss and diarrhea in treating metastatic triple-negative breast cancer.

Peptide-based PROTACs show promise in targeting hard-to-treat proteins, especially for cancer therapy.

Nano-PROTACs could improve drug targeting and delivery by using nanotechnology.

Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.

PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.

Provenge extends prostate cancer survival by about 4 months.

Researchers developed promising agents for prostate cancer imaging, with the best one showing high potential for clinical use.

Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.

Talquetamab may cause hair loss and skin issues.

Trastuzumab deruxtecan is effective for HER2-positive breast cancer but requires careful management of side effects.

Smart nano-PROTACs improve cancer treatment by targeting proteins more precisely and reducing side effects.

Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.

Trastuzumab may cause tufted hair folliculitis as a side effect.

CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.

Sacituzumab Govitecan is effective for certain breast cancers but requires careful management of side effects.